Microdose GLP-1 for PCOS: A Gentler Protocol for Insulin Resistance

Standard-dose GLP-1 protocols are calibrated for significant weight loss — the trial curves were designed to maximize body-weight reduction in patients with obesity. For PCOS patients with significant weight to lose, those protocols fit well. But not every PCOS patient has significant weight to lose, and not every PCOS patient should be on a protocol designed primarily for that goal.

Microdose GLP-1 protocols use lower weekly doses calibrated to capture the insulin-sensitivity and cycle benefits of GLP-1 therapy without producing significant weight loss. For a subset of PCOS patients — particularly those with lean PCOS, those near their target weight, and those who have struggled with GI tolerability on standard doses — microdosing is the right way to use the medication class. This post walks through who fits the microdose protocol, what the dosing logic looks like, and what to expect on it.

Why microdose at all in PCOS

PCOS is a metabolic condition first. The cycle irregularity, androgen excess, and weight retention all trace back to insulin resistance. When clinicians treat the insulin resistance and the weight together, the downstream symptoms improve.

For a patient with significant weight to lose, treating both arms aggressively — standard-dose GLP-1 plus lifestyle plus possibly metformin or inositol — is appropriate. The weight loss arm is doing real clinical work. The trial-curve doses produce 15–22% body-weight reduction, and the metabolic benefits of that magnitude of weight loss are substantial.

But what about a PCOS patient who is already at a healthy BMI? Or a patient five or ten pounds above their target weight? Or a patient with severe GI intolerance to standard-dose titration?

For those patients, the standard-dose protocol is over-engineered. It is producing weight loss they do not need or do not want, at a side-effect cost they may not tolerate. Microdosing reverses the calculus: the dose is calibrated against the metabolic goal (insulin sensitivity, androgen reduction, cycle regularity) rather than the weight goal. The medication is doing the metabolic work without the appetite-suppression intensity that drives the standard-dose weight loss.

This is not a hypothetical use case — it is a clinical reality for a meaningful fraction of PCOS patients seeking GLP-1 therapy. Microdose protocols are how those patients access the metabolic benefits of the medication class.

Who fits a microdose protocol

There are four common candidate profiles for microdose GLP-1 in PCOS:

1. Lean PCOS. Approximately 20–30% of women with PCOS have what is sometimes called the "lean phenotype" — a normal BMI alongside biochemical hyperandrogenism and irregular cycles. The metabolic dysfunction is present (often as insulin resistance detectable on fasting insulin or HOMA-IR), but it is not accompanied by the weight that drives most PCOS care decisions. For these patients, standard-dose GLP-1 may produce weight loss they do not want. Microdose protocols capture the insulin-sensitivity benefits without unnecessary weight reduction.

2. Near-target-weight patients with persistent PCOS symptoms. A patient who has gotten close to a healthy BMI through lifestyle intervention but whose cycles remain irregular and whose insulin markers are still elevated may benefit from a microdose GLP-1 protocol to push the metabolic improvements further. The goal here is not to lose another 15 pounds — it is to keep nudging the insulin axis in the right direction.

3. GI-sensitive patients. Some patients tolerate the standard titration curve poorly — persistent nausea, occasional vomiting, GI dysmotility that does not resolve with the standard escalation cadence. For these patients, the question is whether to discontinue GLP-1 entirely or to stay at a lower dose that the body tolerates. Microdose protocols are often the answer.

4. Maintenance after standard-dose therapy. A patient who has used standard-dose GLP-1 to reach a target weight and improve metabolic markers may transition to a microdose protocol for long-term maintenance. The maintenance dose is lower than the loss-phase dose and is designed to prevent rebound while minimizing ongoing side-effect exposure. Recent maintenance trials in the general weight-loss population have validated this pattern; the PCOS-specific evidence is following.

What the dose actually looks like

Microdose GLP-1 in PCOS uses a fraction of the standard trial-curve dose. Specific numbers vary by medication and by patient, but the general framework:

For compounded semaglutide, microdose protocols often start at 0.125–0.25 mg weekly and titrate gradually as needed — well below the standard escalation curve that targets 1.0–2.4 mg weekly for weight loss.

For compounded tirzepatide, microdose protocols often start at 1.25–2.5 mg weekly — below the standard escalation curve that targets 7.5–15 mg weekly.

The escalation cadence is also gentler. Standard protocols escalate every four weeks toward a target dose. Microdose protocols stay at the same dose for longer, often eight weeks or more, while the clinician evaluates response on metabolic and cycle endpoints rather than scale change.

These numbers are illustrative — the clinician calibrates the actual dose to the individual patient based on weight, insulin markers, cycle history, and tolerance. The point is that microdose protocols are not just "lower" — they are calibrated against a different goal.

What to expect on a microdose protocol

The timeline for microdose response in PCOS looks like:

Weeks 1–4. Most patients experience minimal side effects at microdose levels. Occasional nausea, mild appetite reduction, and slight GI changes are typical but not pronounced. Weight may be stable or trend down slowly.

Weeks 4–12. Insulin markers typically start to improve at this point. Fasting insulin and HOMA-IR drift down. The clinician may pull fasting labs at the 8-12 week mark to check the metabolic axis. Cycles may not have changed visibly yet — cycle regularization typically takes longer.

Months 3–6. Cycle improvements become more visible. Patients who were anovulatory or had long intervals between cycles often start to see shorter, more regular intervals in this window. Free testosterone and SHBG begin to move in the right direction. Weight has typically declined modestly — for lean PCOS patients, often 2–5 pounds; for near-target patients, 5–10% body weight.

Months 6–12. The metabolic and cycle improvements consolidate. The clinician evaluates whether to maintain the microdose, adjust slightly up or down, or layer in other PCOS therapies (metformin, inositol) for the long term. Many microdose PCOS patients stay on the protocol indefinitely as part of their long-term PCOS management.

Microdose versus other PCOS therapies

A reasonable question: if you have lean PCOS or are near a healthy BMI, why use GLP-1 at all instead of metformin or inositol?

The honest answer is: it depends on the patient. Some lean PCOS patients respond well to metformin and inositol alone and do not need GLP-1. Some respond partially and benefit from layering microdose GLP-1 on top. Some do not respond to metformin or inositol and need a different mechanism — GLP-1 acts on different pathways and produces different effects.

The decision is made individually. The microdose GLP-1 protocol exists as an option for PCOS patients who would benefit from the medication class but do not need or want the magnitude of weight loss that standard-dose protocols produce. It is not the first choice for every PCOS patient. It is the right choice for a meaningful subset.

How TelePeptide runs microdose PCOS protocols

Microdose protocols at TelePeptide use the same compounded medications as our standard PCOS protocol — semaglutide or tirzepatide, prepared by licensed 503A pharmacies under individual prescription. The difference is in the dose plan, the titration cadence, and the monitoring focus.

During intake, the clinician asks about weight goals, cycle history, insulin and androgen markers (if you have recent labs), and GI history. If your profile fits a microdose protocol, the clinician will lay out a dose plan that targets the metabolic and cycle improvements rather than significant weight loss. The pricing is the same as the standard protocol — the dose is a clinical decision, not a pricing tier.

For patients with TTC plans, the microdose protocol still requires the same washout windows as standard-dose protocols. The medication is the same; only the dose is different. If TTC is on your near-term horizon, that conversation happens at intake.

Compounded medications are not FDA-approved. GLP-1 use for PCOS is off-label, supported by the 2023 International Evidence-Based PCOS Guideline as an option for metabolic management.

---

This article is for education, not medical advice. Whether microdose GLP-1 fits your PCOS picture is a clinical decision made with your prescribing clinician based on your individual profile.